Skip to content
Troglitazone
Prelay, Rezulin (troglitazone) is a small molecule pharmaceutical. Troglitazone was first approved as Rezulin on 1997-01-29. It is used to treat type 2 diabetes mellitus in the USA. The pharmaceutical is active against peroxisome proliferator-activated receptor gamma. In addition, it is known to target transient receptor potential cation channel subfamily M member 3.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Troglitazone
Tradename
Company
Number
Date
Products
REZULINPfizerN-020720 DISCN1997-01-29
3 products
PRELAYSankyoN-020719 DISCN1997-01-29
3 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
type 2 diabetes mellitusEFO_0001360D003924E11
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BG: Thiazolidinediones, blood glucose lowering drugs
— A10BG01: Troglitazone
HCPCS
No data
Clinical
Clinical Trials
17 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B202—6—412
Pneumocystis pneumoniaD011020EFO_0007448B592—6—412
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SarcomaD01250912———3
Colorectal neoplasmsD015179—1———1
Pancreatic neoplasmsD010190EFO_0003860C25—1———1
LeukemiaD007938C95—1———1
LymphomaD008223C85.9—1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTROGLITAZONE
INNtroglitazone
Description
Troglitazone is a member of chromanes and a thiazolidinone. It has a role as a hypoglycemic agent, an antioxidant, a vasodilator agent, an anticonvulsant, an anticoagulant, a platelet aggregation inhibitor, an antineoplastic agent, an EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor and a ferroptosis inhibitor.
Classification
Small molecule
Drug classperoxisome proliferator activiating receptor (PPAR) agonists (thiazolidene derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cc1c(C)c2c(c(C)c1O)CCC(C)(COc1ccc(CC3SC(=O)NC3=O)cc1)O2
Identifiers
PDB6DGO
CAS-ID97322-87-7
RxCUI72610
ChEMBL IDCHEMBL408
ChEBI ID9753
PubChem CID5591
DrugBankDB00197
UNII IDI66ZZ0ZN0E (ChemIDplus, GSRS)
Target
Agency Approved
PPARG
PPARG
Organism
Homo sapiens
Gene name
PPARG
Gene synonyms
NR1C3
NCBI Gene ID
5468
Protein name
peroxisome proliferator-activated receptor gamma
Protein synonyms
Nuclear receptor subfamily 1 group C member 3, peroxisome proliferator-activated receptor-gamma 5, peroxisome proliferator-activated receptor-gamma splicing, PPAR-gamma
Uniprot ID
Q96J12
Mouse ortholog
Pparg (19016)
peroxisome proliferator-activated receptor gamma (P37238)
Alternate
TRPM3
TRPM3
Organism
Homo sapiens
Gene name
TRPM3
Gene synonyms
KIAA1616, LTRPC3
NCBI Gene ID
80036
Protein name
transient receptor potential cation channel subfamily M member 3
Protein synonyms
Long transient receptor potential channel 3, LTrpC-3, LTrpC3, Melastatin-2, MLSN2
Uniprot ID
Q9HCF6
Mouse ortholog
—
—
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 7,998 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details